Primary sclerosing cholangitis with moderately elevated serum-IgG4 - characterization and outcome of a distinct variant phenotype.
immunoglobulin G4
immunoglobulin G4-related disease
primary sclerosing cholangitis
survival
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
revised:
24
07
2021
received:
28
02
2021
accepted:
26
07
2021
pubmed:
31
7
2021
medline:
4
3
2022
entrez:
30
7
2021
Statut:
ppublish
Résumé
Immunoglobulin G4-associated cholangitis (IAC) is characterized by distinctly elevated immunoglobulin G4 in serum (sIgG4) and responds well to corticosteroid therapy. Primary Sclerosing Cholangitis (PSC) is a progressive liver disease without causal treatment options usually not responding to immunosuppression. Increased serum levels of sIgG4 in patients with PSC, that do not meet criteria of IAC, have been reported in 10%-25%. Therefore, we aimed to characterize this subgroup of patients in a retrospective, multicenter study. sIgG4 values of 289 patients with PSC from three German university hospitals were analysed. Patients with elevated sIgG4 levels were identified and further characterized by clinical and biochemical parameters and by cholangiographic presentation. Clinical endpoints, death and liver transplantation were compared between groups. Parameters associated with outcome were identified with Cox regression analysis. 14.5% of patients with PSC showed increased sIgG4 levels (PSC-IgG4), presented with significantly higher (P < .02) albumin, aspartate-aminotransferase, bilirubin and alkaline phosphatase and had a significant lower prevalence of a concomitant autoimmune hepatitis (P = .025). Cholangiogram obtained via ERC showed extrahepatic dominant strictures more often in the PSC-IgG4 subgroup (P = .047). The disease severity models Amsterdam-Oxford-Score (P = .018) and Mayo-Risk-Score (P = .025) predicted lower survival rates for the PSC-IgG4 subgroup. Transplant-free survival after first diagnosis of PSC was shorter in patients with elevated sIgG4 (11.6 vs 15.1 years, P = .001). Patients with PSC and elevated sIgG4 should be considered as a distinct subgroup, characterized by different clinical and cholangiographical features and are associated with an inferior outcome.
Sections du résumé
BACKGROUND AND AIMS
Immunoglobulin G4-associated cholangitis (IAC) is characterized by distinctly elevated immunoglobulin G4 in serum (sIgG4) and responds well to corticosteroid therapy. Primary Sclerosing Cholangitis (PSC) is a progressive liver disease without causal treatment options usually not responding to immunosuppression. Increased serum levels of sIgG4 in patients with PSC, that do not meet criteria of IAC, have been reported in 10%-25%. Therefore, we aimed to characterize this subgroup of patients in a retrospective, multicenter study.
METHODS
sIgG4 values of 289 patients with PSC from three German university hospitals were analysed. Patients with elevated sIgG4 levels were identified and further characterized by clinical and biochemical parameters and by cholangiographic presentation. Clinical endpoints, death and liver transplantation were compared between groups. Parameters associated with outcome were identified with Cox regression analysis.
RESULTS
14.5% of patients with PSC showed increased sIgG4 levels (PSC-IgG4), presented with significantly higher (P < .02) albumin, aspartate-aminotransferase, bilirubin and alkaline phosphatase and had a significant lower prevalence of a concomitant autoimmune hepatitis (P = .025). Cholangiogram obtained via ERC showed extrahepatic dominant strictures more often in the PSC-IgG4 subgroup (P = .047). The disease severity models Amsterdam-Oxford-Score (P = .018) and Mayo-Risk-Score (P = .025) predicted lower survival rates for the PSC-IgG4 subgroup. Transplant-free survival after first diagnosis of PSC was shorter in patients with elevated sIgG4 (11.6 vs 15.1 years, P = .001).
CONCLUSION
Patients with PSC and elevated sIgG4 should be considered as a distinct subgroup, characterized by different clinical and cholangiographical features and are associated with an inferior outcome.
Substances chimiques
Immunoglobulin G
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2924-2933Informations de copyright
© 2021 The Authors. Liver International published by John Wiley & Sons Ltd.
Références
Washington MK. Autoimmune liver disease: overlap and outliers. Mod Pathol. 2007;20(S1):S15-S30. https://doi.org/10.1038/modpathol.3800684
Dalekos GN, Gatselis NK. Variant and specific forms of autoimmune cholestatic liver diseases. Arch Immunol Ther Exp (Warsz). 2019;67(4):197-211. https://doi.org/10.1007/s00005-019-00550-9
Strassburg CP, Beckebaum S, Geier A, et al. Clinical practice guideline autoimmune liver diseases. Z Gastroenterol. 2017;55(11):1135-1226. https://doi.org/10.1055/s-0043-120199
Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis - a comprehensive review. J Hepatol. 2017;67(6):1298-1323. https://doi.org/10.1016/j.jhep.2017.07.022
Weismüller TJ, Wedemeyer J, Kubicka S, Strassburg CP, Manns MP. The challenges in primary sclerosing cholangitis - Aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol. 2008;48:S38-S57. https://doi.org/10.1016/j.jhep.2008.01.020
Nakamoto N, Sasaki N, Aoki R, et al. Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. Nat Microbiol. 2019;4(3):492-503. https://doi.org/10.1038/s41564-018-0333-1
Maroni L, Ninfole E, Pinto C, Benedetti A, Marzioni M. Gut-liver axis and inflammasome activation in cholangiocyte pathophysiology. Cells. 2020;9(3):736. https://doi.org/10.3390/cells9030736
Alberts R, de Vries EMGG, Goode EC, et al. Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. Gut. 2018;67(8):1517-1524. https://doi.org/10.1136/gutjnl-2016-313598
Karlsen TH, Franke A, Melum E, et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterol. 2010;138(3):1102-1111. https://doi.org/10.1053/j.gastro.2009.11.046
Kunzmann LK, Schoknecht T, Poch T, et al. Monocytes as potential mediators of pathogen-induced T-helper 17 differentiation in patients With Primary Sclerosing Cholangitis (PSC). Hepatol. 2020;72(4):1310-1326. https://doi.org/10.1002/hep.31140
Ravichandran G, Neumann K, Berkhout LK, et al. Interferon-γ-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice. J Hepatol. 2019;71(4):773-782. https://doi.org/10.1016/j.jhep.2019.05.023
Liaskou E, Jeffery LE, Trivedi PJ, et al. Loss of CD28 expression by liver-infiltrating T cells contributes to pathogenesis of primary sclerosing cholangitis. Gastroenterol. 2014;147(1):221-232.e7. https://doi.org/10.1053/j.gastro.2014.04.003
Kim WR, Therneau TM, Wiesner RH, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc. 2000;75(7):688-694. https://doi.org/10.4065/75.7.688
de Vries EM, Wang J, Williamson KD, et al. A novel prognostic model for transplant-free survival in primary sclerosing cholangitis. Gut. 2018;67(10):1864-1869. https://doi.org/10.1136/gutjnl-2016-313681
Hubers LM, Maillette de Buy Wenniger LJ, Doorenspleet ME, et al. IgG4-associated cholangitis: a comprehensive review. Clin Rev Allergy Immunol. 2015;48(2-3):198-206. https://doi.org/10.1007/s12016-014-8430-2
Boonstra K, Culver EL, de Buy Wenniger LM, et al. Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis. Hepatol. 2014;59(5):1954-1963. https://doi.org/10.1002/hep.26977
Kamisawa T, Nakazawa T, Tazuma S, et al. Clinical practice guidelines for IgG4-related sclerosing cholangitis. J Hepatobiliary Pancreat Sci. 2019;26(1):9-42. https://doi.org/10.1002/jhbp.596
Weismüller TJ, Trivedi PJ, Bergquist A, et al. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterol. 2017;152(8):1975-1984.e8. https://doi.org/10.1053/j.gastro.2017.02.038
Huggett MT, Culver EL, Kumar M, et al. Type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort. Am J Gastroenterol. 2014;109(10):1675-1683. https://doi.org/10.1038/ajg.2014.223
Ali AH, Bi Y, Machicado JD, et al. The long-term outcomes of patients with immunoglobulin G4-related sclerosing cholangitis: the Mayo Clinic experience. J Gastroenterol. 2020;55(11):1087-1097. https://doi.org/10.1007/s00535-020-01714-7
Mendes FD, Jorgensen R, Keach J, et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2006;101(9):2070-2075. https://doi.org/10.1111/j.1572-0241.2006.00772.x
Benito de Valle M, Müller T, Björnsson E, et al. The impact of elevated serum IgG4 levels in patients with primary sclerosing cholangitis. Dig Liver Dis. 2014;46(10):903-908. https://doi.org/10.1016/j.dld.2014.06.010
Koyabu M, Uchida K, Fukata N, et al. Primary sclerosing cholangitis with elevated serum IgG4 levels and/or infiltration of abundant IgG4-positive plasma cells. J Gastroenterol. 2010;45(1):122-129. https://doi.org/10.1007/s00535-009-0130-y
European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51(2):237-267. https://doi.org/10.1016/j.jhep.2009.04.009
Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohn's Colitis. 2019;13(2):144-164K. https://doi.org/10.1093/ecco-jcc/jjy113
Kucharzik T, Dignass AU, Atreya R, et al. Aktualisierte S3-leitlinie colitis ulcerosa - living guideline: august 2020 - AWMF-registriernummer: 021-009. Z Gastroenterol. 2020;58(12):e241-e326. https://doi.org/10.1055/a-1296-3444
Preiß J, Bokemeyer B, Buhr H, et al. Aktualisierte S3-leitlinie - “Diagnostik und Therapie des Morbus Crohn” 2014 1: AWMF-registriernummer: 021-004. Z Gastroenterol. 2014;52(12):1431-1484. https://doi.org/10.1055/s-0034-1385199
Manganis CD, Chapman RW, Culver EL. Review of primary sclerosing cholangitis with increased IgG4 levels. World J Gastroenterol. 2020;26(23):3126-3144. https://doi.org/10.3748/wjg.v26.i23.3126
Alswat K, Al-Harthy N, Mazrani W, Alshumrani G, Jhaveri K, Hirschfield GM. The spectrum of sclerosing cholangitis and the relevance of IgG4 elevations in routine practice. Am J Gastroenterol. 2012;107(1):56-63. https://doi.org/10.1038/ajg.2011.375
Stone JH, Brito-Zerón P, Bosch X, Ramos-Casals M. Diagnostic approach to the complexity of IgG4-related disease. Mayo Clin Proc. 2015;90(7):927-939. https://doi.org/10.1016/j.mayocp.2015.03.020
Hildebrand T, Pannicke N, Dechene A, et al. Biliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis: a retrospective multicenter analysis. Liver Transplant. 2016;22(1):42-52. https://doi.org/10.1002/lt.24350
Navaneethan U, GK Venkatesh P, Choudhary M, Shen BO, Kiran RP. Elevated immunoglobulin G4 level is associated with reduced colectomy-free survival in patients with primary sclerosing cholangitis and ulcerative colitis. J Crohn's Colitis. 2013;7(2):e35-e41. https://doi.org/10.1016/j.crohns.2012.04.006
Lee HE, Zhang L. Immunoglobulin G4-related hepatobiliary disease. Semin Diagn Pathol. 2019;36(6):423-433. https://doi.org/10.1053/j.semdp.2019.07.007
Minaga K, Watanabe T, Chung H, Kudo M. Autoimmune hepatitis and IgG4-related disease. World J Gastroenterol. 2019;25(19):2308-2314. https://doi.org/10.3748/wjg.v25.i19.2308
Tabata T, Kamisawa T, Takuma K, et al. Serial changes of elevated serum IgG4 levels in IgG4-related systemic disease. Intern Med. 2011;50(2):69-75. https://doi.org/10.2169/internalmedicine.50.4321
Björnsson E, Chari S, Silveira M, et al. Primary sclerosing cholangitis associated with elevated immunoglobulinG4: clinical characteristics and response to therapy. Am J Ther. 2011;18(3):198-205. https://doi.org/10.1097/MJT.0b013e3181c9dac6
Carruthers MN, Stone JH, Deshpande V, Khosroshahi A. Development of an IgG4-RD responder index. Int J Rheumatol. 2012;2012:1-7. https://doi.org/10.1155/2012/259408
Culver EL, Williamson KD, Halliday J, et al. Elevated serum and tissue levels of IgG4 in primary sclerosing cholangitis are associated with a worse clinical outcome. Hepatol. 2012;56(4 suppl):1131A.
Tanaka A. IgG4-related sclerosing cholangitis and primary sclerosing cholangitis. Gut Liv. 2019;13(3):300-307. https://doi.org/10.5009/gnl18085
Boonstra K, Weersma RK, van Erpecum KJ, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatol. 2013;58(6):2045-2055. https://doi.org/10.1002/hep.26565
Ponsioen CY, Vrouenraets SME, Prawirodirdjo W, et al. Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut. 2002;51(4):562-566. https://doi.org/10.1136/gut.51.4.562
Gotthardt D, Stiehl A. Endoscopic retrograde cholangiopancreatography in diagnosis and treatment of primary sclerosing cholangitis. Clin Liver Dis. 2010;14(2):349-358. https://doi.org/10.1016/j.cld.2010.03.010
Fischer S, Trivedi PJ, Ward S, Greig PD, Therapondos G, Hirschfield GM. Frequency and significance of IgG4 immunohistochemical staining in liver explants from patients with primary sclerosing cholangitis. Int J Exp Pathol. 2014;95(3):209-215. https://doi.org/10.1111/iep.12076